How Do Asthma Treatment Guidelines Work Step by Step?
At a Glance
The stepwise asthma approach adjusts medication to symptom control: doctors increase treatment when symptoms or flare-ups persist and may reduce it after at least 3 months of stable control. The goal is the lowest effective treatment, not stopping inhaled corticosteroids without guidance.
In this answer
3 sections
The stepwise approach to asthma treatment is a system that doctors use to prescribe and adjust your asthma medications over time based on how well your symptoms are controlled. Instead of keeping you on the same dose forever, your doctor will “step up” (increase) your medication intensity if your asthma is acting up, and “step down” (decrease) it once your breathing has been stable for a while [1][2]. This dynamic process aims to find the lowest amount of medicine needed to maintain control and reduce the risk of flare-ups [3][2].
Note: The following framework applies to adults and adolescents (12 years and older). Treatment steps for children under 12, pregnant individuals, or based on specific country guidelines may differ.
The GINA Guidelines (Steps 1 through 5)
The most widely used framework for this approach comes from the Global Initiative for Asthma (GINA). GINA divides asthma treatment into five steps, which represent the intensity of treatment needed, not a fixed category of severity. Even people on lower-intensity steps can be at risk for severe asthma attacks [4].
GINA recommends two main tracks for adults and adolescents.
Track 1 (Preferred Approach)
Track 1 uses an inhaler containing an inhaled corticosteroid (ICS—which reduces airway inflammation) combined with formoterol, a rapid-onset, long-acting airway opener [5][6].
- Steps 1 and 2 (Lower-Intensity Treatment): You use a low-dose ICS-formoterol inhaler only as needed when you have symptoms or before exercise [5]. You do not use a daily maintenance inhaler at this stage.
- Steps 3 and 4 (Medium-Intensity Treatment): You take an approved ICS-formoterol inhaler every day as maintenance to control inflammation, and use that same inhaler as a rescue medication when symptoms flare up [5][7]. This is called MART (Maintenance and Reliever Therapy). Step 4 simply involves a higher daily maintenance dose than Step 3. Note: Only specific ICS-formoterol inhalers are approved for MART. Do not try this with other inhalers.
- Step 5 (Specialist Assessment / Add-On Treatment): If asthma is uncontrolled at Step 4, you will likely be referred to a specialist. After reviewing your condition, they may add therapies such as long-acting muscarinic antagonists (LAMAs) [5]. For selected patients, they might prescribe azithromycin (an antibiotic taken on specific days of the week, requiring careful monitoring for side effects) or targeted biologic therapies (injections or IV infusions for specific asthma subtypes) [8].
Track 2 (Alternative Approach)
Track 2 is used when Track 1 is not suitable. It relies on a traditional short-acting rescue inhaler (like albuterol, known as a SABA) [9].
- Step 1: You take a low-dose ICS inhaler every time you use your SABA rescue inhaler [6].
- Step 2: You use a daily ICS maintenance inhaler, plus your SABA as needed [9].
- Steps 3 through 5: You use a daily combination inhaler (ICS plus a long-acting bronchodilator, or LABA), plus your SABA as needed [6].
GINA no longer recommends using only a SABA rescue inhaler without any ICS medication, as adding the ICS reduces the risk of severe asthma attacks [10][5].
Stepping Up Treatment and Urgent Action
If you are using your rescue inhaler frequently, waking up at night with coughing, or having asthma attacks, your doctor will consider stepping up your treatment [1].
However, increased reliever use is a warning sign. Never change your maintenance dose on your own unless your doctor has provided a written asthma action plan instructing you to do so. If you are severely short of breath, cannot speak in full sentences, have blue lips, feel unusually drowsy, or if your rescue inhaler is not helping, seek emergency medical care immediately.
During a routine visit, before prescribing a stronger dose, your doctor will evaluate other factors. They will check your lung function, ensure you are using your inhaler correctly, verify you aren’t missing doses, and look for triggers like smoking, allergies, or other health conditions [4][11][12]. Fixing poor inhaler technique or managing triggers can often improve control without needing a higher medication dose [12].
Stepping Down Treatment
If your symptoms have been well-controlled and stable for at least 3 months, your doctor may discuss stepping down your treatment [13]. The goal is to find the minimum effective dose [3][14].
Stepping down usually involves lowering the dose or frequency of your daily ICS inhaler [3]. Generally, doctors advise against stopping your ICS medication entirely, as completely withdrawing it increases the risk of severe flare-ups [3][14]. This process must be carefully supervised, guided by a written action plan, and followed by an appointment to ensure your breathing remains stable [15].
Common questions in this guide
What does the stepwise approach to asthma treatment mean?
What are the five GINA asthma treatment steps?
Can the same inhaler be used every day and for quick relief?
When might my doctor increase my asthma treatment?
When is it safe to reduce asthma medicine?
What asthma symptoms require emergency care?
What if an ICS-formoterol inhaler is not right for me?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Adjusting treatment steps
When might my doctor consider stepping down my asthma treatment?
Action plans
Should I ask my doctor for a written asthma action plan?
Inhaler use and triggers
Could improving my inhaler technique help my control without a higher dose?
Related questions
Get notified when new evidence is published on asthma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Treatment strategies for asthma: reshaping the concept of asthma management.
Papi A, Blasi F, Canonica GW, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020; (16()):75 doi:10.1186/s13223-020-00472-8.
PMID: 32944030 - 2
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.
Reddel HK, Bacharier LB, Bateman ED, et al.
American journal of respiratory and critical care medicine 2022; (205(1)):17-35 doi:10.1164/rccm.202109-2205PP.
PMID: 34658302 - 3
The Asthma Controller Step-down Yardstick.
Chipps BE, Bacharier LB, Murphy KR, et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2019; (122(3)):241-262.e4 doi:10.1016/j.anai.2018.12.004.
PMID: 30550809 - 4
A summary of the new GINA strategy: a roadmap to asthma control.
Reddel HK, Bateman ED, Becker A, et al.
The European respiratory journal 2015; (46(3)):622-39 doi:10.1183/13993003.00853-2015.
PMID: 26206872 - 5
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.
Reddel HK, Bacharier LB, Bateman ED, et al.
Respirology (Carlton, Vic.) 2022; (27(1)):14-35 doi:10.1111/resp.14174.
PMID: 34668278 - 6
Update on Asthma Management Guidelines.
Dubin S, Patak P, Jung D
Missouri medicine 2024; (121(5)):364-367.
PMID: 39421468 - 7
A Practical Guide to Implementing SMART in Asthma Management.
Reddel HK, Bateman ED, Schatz M, et al.
The journal of allergy and clinical immunology. In practice 2022; (10(1S)):S31-S38 doi:10.1016/j.jaip.2021.10.011.
PMID: 34666208 - 8
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
Holguin F, Cardet JC, Chung KF, et al.
The European respiratory journal 2020; (55(1)) doi:10.1183/13993003.00588-2019.
PMID: 31558662 - 9
Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 study.
Chapman KR, Canonica GW, Lavoie KL, et al.
Respiratory medicine 2022; (201()):106948 doi:10.1016/j.rmed.2022.106948.
PMID: 36029695 - 10
ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis.
Hatter L, Bruce P, Braithwaite I, et al.
ERJ open research 2021; (7(1)) doi:10.1183/23120541.00701-2020.
PMID: 33532465 - 11
Identifying future risk factors of uncontrolled asthma control: the TAAR study perspective.
Bozkurt N, Abadoglu O, Onaran ABO, et al.
The Journal of asthma : official journal of the Association for the Care of Asthma 2026; (63(3)):339-349 doi:10.1080/02770903.2025.2592244.
PMID: 41305966 - 12
"Trying, But Failing" - The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence.
Braido F, Chrystyn H, Baiardini I, et al.
The journal of allergy and clinical immunology. In practice 2016; (4(5)):823-32.
PMID: 27587316 - 13
A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma.
Usmani OS, Kemppinen A, Gardener E, et al.
The journal of allergy and clinical immunology. In practice 2017; (5(5)):1378-1387.e5 doi:10.1016/j.jaip.2017.02.006.
PMID: 28351782 - 14
Why and how to step down chronic asthma drugs.
Gionfriddo MR, Hagan JB, Rank MA
BMJ (Clinical research ed.) 2017; (359()):j4438 doi:10.1136/bmj.j4438.
PMID: 29038166 - 15
Pragmatic Randomized Controlled Trial for Stepping Down Asthma Controller Treatment in Patients Controlled with Low-Dose Inhaled Corticosteroid and Long-Acting β2-Agonist: Step-Down of Intervention and Grade in Moderate Asthma Study.
Kim SH, Lee T, Jang AS, et al.
The journal of allergy and clinical immunology. In practice 2021; (9(10)):3638-3646.e3 doi:10.1016/j.jaip.2021.04.042.
PMID: 33940213
This page is for informational purposes only and does not constitute medical advice. Do not change asthma medicines without your clinician's guidance; seek emergency care for severe breathing symptoms.